01Pathophysiological Background
Procollagen type I C-terminal propeptide (PICP) is a 100 kDa globular peptide stoichiometrically cleaved from procollagen type I during extracellular matrix synthesis by bone morphogenetic protein 1 (BMP-1) and related procollagen C-proteinases. Each molecule of mature collagen type I fiber deposited in the myocardial interstitium releases exactly one molecule of PICP into the circulation, making it a near-stoichiometric serum index of de novo collagen type I synthesis.
In the context of a unicameral leadless pacemaker (such as the Abbott Aveir VR or Medtronic Micra AV/VR), patients implanted for complete atrioventricular block or sick sinus syndrome may accumulate a right ventricular (RV) pacing burden exceeding 90–97%. Chronic dyssynchronous RV activation generates regional wall-motion abnormalities, abnormal septal curvature, and spatially heterogeneous myocardial strain — mechanical stimuli that activate fibroblasts, up-regulate TGF-β1 signaling, and drive progressive interstitial collagen deposition.
Myocardial fibrosis in high-burden RV pacing typically precedes measurable EF decline by 12–24 months. PICP elevation may represent the earliest detectable signal of pacing-induced cardiomyopathy (PICM), creating a critical diagnostic window for prophylactic upgrade to conduction system pacing.
Unlike replacement (focal) fibrosis — detectable by late gadolinium enhancement (LGE) on cardiac MRI — the early fibrotic response in PICM is predominantly reactive interstitial fibrosis, distributed diffusely and not visible on standard imaging. Serum PICP, alongside T1 mapping-derived extracellular volume (ECV), targets this clinically silent but hemodynamically consequential process.
02Serum PICP ELISA — The Index Test
Serum PICP is quantified by immunoassay, most commonly competitive or sandwich ELISA. Commercial kits from manufacturers including Metra Biosystems and Orion Diagnostica have been used in research settings; in clinical practice, PICP is typically ordered as a send-out test through reference laboratories specializing in bone and connective tissue markers.
| Parameter | Value / Range | Clinical Interpretation |
|---|---|---|
| Normal Reference Range | 50–170 µg/L | Normal |
| Borderline Elevation | 170–200 µg/L | Monitor Closely |
| Significant Elevation | >200 µg/L | Active Fibrosis |
| Diurnal Variation | Peak: morning | Fasting AM Sample |
| Exercise Effect | Transient ↑ post-exercise | 48h Exercise-Free |
| Renal Confounding | ↑ in CKD/AKI (reduced clearance) | Record eGFR |
Pre-Analytical Considerations
Optimal specimen handling requires fasting venous blood collected in the morning, with serum separation within 2 hours. PICP is stable in serum at −20 °C for up to 12 months. Critical pre-analytical confounders include:
- Vigorous exercise: transient PICP elevation of 15–30% has been documented after intense aerobic exercise; a 48-hour exercise-free window prior to sampling is recommended in active patients, particularly competitive athletes.
- Renal function: PICP undergoes hepatic and renal clearance; CKD stage 3b or higher may elevate baseline values by 20–40%.
- Medications: ACE inhibitors, ARBs, and aldosterone antagonists attenuate myocardial fibrosis and may suppress PICP; document current RAAS-blocking therapy.
Serum PICP is not routinely available at most US hospital clinical laboratories. Clinicians should anticipate 5–10 business days for results via specialty reference laboratory send-out. Galectin-3 and sST2 offer commercially available, rapid-turnaround alternatives with overlapping clinical utility.
03Companion Biomarker Panel
Given the modest standalone specificity of PICP for myocardial — as opposed to systemic — fibrosis, a multimarker strategy substantially increases diagnostic accuracy in the pacemaker patient. The recommended panel integrates markers of collagen synthesis, collagen degradation balance, fibrosis signaling, and myocardial wall stress.
| Biomarker | Mechanism | Availability | Fibrosis Threshold |
|---|---|---|---|
| PICP | Collagen type I synthesis | Send-out | >200 µg/L |
| PIIINP | Collagen type III synthesis | Send-out | >4.2 µg/L |
| MMP-1 / TIMP-1 ratio | Collagenase/inhibitor balance | Send-out | Ratio <1 → net fibrosis |
| Galectin-3 | Macrophage fibrosis signaling | Routine lab | >17.8 ng/mL |
| sST2 (soluble ST2) | IL-33/ST2 fibrosis pathway | Routine lab | >35 ng/mL (HF risk) |
| NT-proBNP | Wall stress / volume overload | Universal | Age- and renal-adjusted |
Galectin-3: The Pragmatic Surrogate
Galectin-3 is an FDA-cleared biomarker for risk stratification in heart failure, commercially available at virtually all US clinical laboratories. It is secreted by activated cardiac macrophages and directly stimulates fibroblast proliferation and collagen synthesis. In HFpEF and heart failure with preserved ejection fraction — the phenotype most analogous to early PICM — galectin-3 above 17.8 ng/mL independently predicts adverse outcomes and correlates with histologically confirmed increased collagen volume fraction.
Soluble ST2
sST2 (soluble suppression of tumorigenicity 2) acts as a decoy receptor for IL-33, a cardioprotective cytokine. Elevated sST2 reduces IL-33 signaling, disinhibiting fibroblast activation. In patients with structural heart disease from pacing, sST2 elevation reflects both myocardial mechanical stress and pro-fibrotic signaling, making it a sensitive early marker — though less specific than PICP for collagen synthesis per se.
04Serial Measurement Strategy
A single PICP measurement carries limited prognostic value. The diagnostic power of PICP in PICM surveillance lies in its longitudinal trajectory. A rising PICP trend — even within the normal absolute range — over 6–12 months of high-burden pacing represents an actionable signal of accelerating fibrogenesis.
In patients without a pre-implant baseline (e.g., urgent implantation for complete heart block), two sequential measurements 6 months apart establish a trajectory. A >20% rise in PICP over 6 months, in the presence of high pacing burden, should be considered clinically significant regardless of absolute value.
05Cardiac MRI: T1 Mapping & ECV Quantification
Cardiovascular magnetic resonance (CMR) with T1 mapping and extracellular volume (ECV) fraction quantification is the most validated non-invasive imaging correlate of diffuse interstitial myocardial fibrosis, and serves as the bridge between serum biomarkers and histological confirmation.
ECV Interpretation
ECV is derived from native and post-gadolinium T1 maps corrected for hematocrit, and directly estimates the myocardial extracellular compartment. Normal myocardial ECV is approximately 25–28%. Values exceeding 28–30% indicate expanded extracellular matrix and are associated with histologically confirmed interstitial fibrosis. ECV above 32% in a paced patient correlates strongly with reduced contractile reserve and identifies patients least likely to recover function after CRT or LBBAP upgrade.
LGE vs. T1 Mapping: Complementary Roles
Late gadolinium enhancement (LGE) identifies focal replacement fibrosis (irreversible scar) and is insensitive to the diffuse reactive fibrosis that characterizes early PICM. Native T1 mapping and ECV target this diffuse component. Therefore, in a leadless pacemaker patient with preserved EF and early diastolic dysfunction, a normal LGE does not exclude significant myocardial fibrosis — T1/ECV mapping is mandatory for complete fibrosis assessment.
The Abbott Aveir VR leadless pacemaker is labeled MRI conditional at 1.5T under specific conditions. The Medtronic Micra VR/AV devices are also MRI conditional. Before scheduling CMR, verify current device labeling, confirm compliance with scan parameter requirements, and ensure appropriate programming pre- and post-scan. Not all 3T protocols are approved.
06Endomyocardial Biopsy — Reference Standard
Endomyocardial biopsy (EMB) with histomorphometric analysis remains the definitive reference standard for myocardial fibrosis quantification. Picrosirius red staining under polarized light microscopy distinguishes collagen type I (thick fibers, red-orange birefringence) from collagen type III (thin fibers, green birefringence), enabling collagen volume fraction (CVF) and type I/III ratio calculation.
EMB is not appropriate for routine PICM surveillance. Its role is limited to research protocols, enrolment in device upgrade trials requiring histological endpoints, or atypical presentations where alternative etiologies (infiltrative disease, storage disorders, myocarditis) must be excluded before attributing cardiomyopathy to pacing.
In published PICM biopsy series, CVF in high-burden RV-paced patients averages 15–22% vs. 3–6% in controls. A CVF above 15% at biopsy correlates with incomplete LV function recovery after CRT upgrade, reinforcing the value of early non-invasive detection.
07Practical Diagnostic Pathway
The following stepwise approach integrates biomarker surveillance with imaging for the management of the high-burden RV-paced leadless pacemaker patient:
-
Establish Current Biomarker Baseline Order: Galectin-3, sST2, NT-proBNP (routine labs). Request PICP + PIIINP via specialty send-out lab. Document eGFR and current RAAS therapy. Ensure 48h exercise-free window pre-sampling.
-
Echocardiographic Fibrosis Surrogates Request comprehensive echo with GLS (global longitudinal strain) by speckle tracking, E/e' ratio, left atrial volume index (LAVI), and diastolic dysfunction grading per ASE/EACVI 2016 criteria. Declining GLS and rising E/e' are the earliest echo signals of fibrosis-mediated dysfunction.
-
CMR with T1 Mapping & ECV Schedule 1.5T CMR (MRI-conditional per device labeling) including native T1 mapping, post-gadolinium T1, hematocrit-corrected ECV quantification, and LGE. ECV >28% confirms interstitial fibrosis independently of echo findings.
-
Integrate Findings for Upgrade Decision Elevated PICP or galectin-3 + abnormal ECV + echocardiographic progression in a patient with ≥90% RV pacing burden constitutes a compelling multimodal evidence base for LBBAP upgrade consultation — even before EF drops below 50%.
-
Post-Upgrade Biomarker Monitoring Repeat PICP and galectin-3 at 6 and 12 months after LBBAP upgrade. Declining PICP trajectory confirms anti-fibrotic remodeling and serves as a surrogate endpoint for procedural efficacy.
08Clinical FAQ
Q: What is PICP and why does it matter in leadless pacemaker patients?
PICP (procollagen type I C-terminal propeptide) is a serum marker of active collagen type I synthesis. In patients with leadless pacemakers and high RV pacing burden, chronic dyssynchronous activation drives myocardial fibrosis that precedes EF decline. PICP elevation signals active fibrogenesis — a reversible substrate if detected early and treated with conduction system pacing upgrade.
Q: What is the reference range for serum PICP?
Normal serum PICP is approximately 50–170 µg/L (laboratory-dependent). Elevations above 200 µg/L in a paced patient with high RV burden, after excluding confounders (CKD, recent intense exercise), are considered clinically significant. Serial rising trends — even within the normal range — carry independent prognostic weight.
Q: Are there commercially available alternatives to PICP for fibrosis detection?
Yes. Galectin-3 (FDA-cleared for HF risk stratification) and soluble ST2 (sST2) are widely available at US reference laboratories, have same-day turnaround, and have been validated in fibrotic cardiac remodeling. They do not measure collagen synthesis directly but reflect pro-fibrotic signaling and serve as practical surrogates when PICP send-out testing is not feasible.
Q: Can the Aveir VR patient undergo cardiac MRI for T1 mapping?
The Abbott Aveir VR is MRI conditional at 1.5T under specific scan parameters defined in the device labeling. T1 mapping and ECV quantification for fibrosis assessment are feasible but require coordination with the implanting center, device programming pre/post-scan, and verification that the specific CMR protocol complies with labeling conditions. 3T compatibility must be verified separately.
Q: When is LBBAP upgrade warranted based on PICP and fibrosis findings?
LBBAP upgrade should be considered when: (1) RV pacing burden exceeds 90%; (2) serum PICP or galectin-3 is elevated or demonstrating rising trajectory; (3) CMR shows ECV >28%; and/or (4) echocardiography documents progressive diastolic dysfunction, rising LAVI, or declining GLS — even before EF falls below 50%. Early intervention targets the reversible fibrotic phase before permanent cardiomyocyte replacement.